A systematic review of the neutrophil to lymphocyte and platelet to lymphocyte ratios in patients with lower extremity arterial disease

被引：3

作者：

Bradley, Nicholas A. ^{[1
]}

Roxburgh, Campbell S. D. ^{[2
]}

McMillan, Donald C. ^{[3
]}

Guthrie, Graeme J. K. ^{[1
]}

机构：

[1] Univ Glasgow, Glasgow, Lanark, Scotland

[2] Univ Glasgow, Surg, Glasgow, Lanark, Scotland

[3] Univ Glasgow, Surg Sci, Glasgow, Lanark, Scotland

来源：

VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE | 2024年 / 53卷 / 03期

关键词：

NLR; PLR; LEAD; CLTI; inflammation; atherosclerosis; BLOOD-COUNT PARAMETERS; CRITICAL LIMB ISCHEMIA; PROGNOSTIC MARKER; INFLAMMATION; AMPUTATION; MORTALITY; MANAGEMENT; SEVERITY; SURVIVAL; OUTCOMES;

D O I：

10.1024/0301-1526/a001117

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Lower extremity arterial disease (LEAD) is caused by atherosclerotic plaque in the arterial supply to the lower limbs. The neutrophil to lymphocyte and platelet to lymphocyte ratios (NLR, PLR) are established markers of systemic inflammation which are related to inferior outcomes in multiple clinical conditions, though remain poorly described in patients with LEAD. This review was carried out in accordance with PRISMA guidelines. The MEDLINE database was interrogated for relevant studies. Primary outcome was the prognostic effect of NLR and PLR on clinical outcomes following treatment, and secondary outcomes were the prognostic effect of NLR and PLR on disease severity and technical success following revascularisation. There were 34 studies included in the final review reporting outcomes on a total of 19870 patients. NLR was investigated in 21 studies, PLR was investigated in two studies, and both NLR & PLR were investigated in 11 studies. Relating to increased levels of systemic inflammation, 20 studies (100%) reported inferior clinical outcomes, 13 (92.9%) studies reported increased disease severity, and seven (87.5%) studies reported inferior technical results from revascularisation. The studies included in this review support the role of elevated NLR and PLR as key components influencing the clinical outcomes, severity, and success of treatment in patients with LEAD. The use of these easily accessible, cost effective and routinely available markers is supported by the present review.

引用

页码：155 / 171

页数：17

共 73 条

[51] Neutrophil to Lymphocyte Ratio as a Predictor of Outcomes after Amputation [J].

Pierre-Louis, Willythssa S. ;

Bath, Jonathan ;

Mikkilineni, Sesank ;

Scott, Michael C. ;

Harlander-Locke, Michael ;

Rasor, Zachary ;

Smeds, Matthew .

ANNALS OF VASCULAR SURGERY, 2019, 54 :84-91

[52] Neutrophil-lymphocyte ratio is a marker of survival and cardiac complications rather than patency following revascularization of lower extremities [J].

Pourafkari, Leili ;

Choi, Catherine ;

Garajehdaghi, Reza ;

Tajlil, Arezou ;

Dosluoglu, Hasan H. ;

Nader, Nader D. .

VASCULAR MEDICINE, 2018, 23 (05) :437-444

[53] Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease [J].

Ridker, P. M. ;

Everett, B. M. ;

Thuren, T. ;

MacFadyen, J. G. ;

Chang, W. H. ;

Ballantyne, C. ;

Fonseca, F. ;

Nicolau, J. ;

Koenig, W. ;

Anker, S. D. ;

Kastelein, J. J. P. ;

Cornel, J. H. ;

Pais, P. ;

Pella, D. ;

Genest, J. ;

Cifkova, R. ;

Lorenzatti, A. ;

Forster, T. ;

Kobalava, Z. ;

Vida-Simiti, L. ;

Flather, M. ;

Shimokawa, H. ;

Ogawa, H. ;

Dellborg, M. ;

Rossi, P. R. F. ;

Troquay, R. P. T. ;

Libby, P. ;

Glynn, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12) :1119-1131

[54] From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? [J].

Ridker, Paul M. .

CARDIOVASCULAR RESEARCH, 2021, 117 (11) :E138-E140

[55]

Roxburgh CS., 2009, Roleof systemic inflammatory response in predicting survival in patients withprimary operable cancer, V6, P149

[56] Recommended standards for reports dealing with lower extremity ischemia: Revised version [J].

Rutherford, RB ;

Baker, JD ;

Ernst, C ;

Johnston, KW ;

Porter, JM ;

Ahn, S ;

Jones, DN .

JOURNAL OF VASCULAR SURGERY, 1997, 26 (03) :517-538

[57] Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies [J].

Sarwar, Nadeem ;

Butterworth, Adam S. ;

Freitag, Daniel F. ;

Gregson, John ;

Willeit, Peter ;

Gorman, Donal N. ;

Gao, Pei ;

Saleheen, Danish ;

Rendon, Augusto ;

Nelson, Christopher P. ;

Braund, Peter S. ;

Hall, Alistair S. ;

Chasman, Daniel I. ;

Tybjaerg-Hansen, Anne ;

Chambers, John C. ;

Benjamin, Emelia J. ;

Franks, Paul W. ;

Clarke, Robert ;

Wilde, Arthur A. M. ;

Trip, Mieke D. ;

Steri, Maristella ;

Witteman, Jacqueline C. M. ;

Qi, Lu ;

van der Schoot, C. Ellen ;

de Faire, Ulf ;

Erdmann, Jeanette ;

Stringham, Heather M. ;

Koenig, Wolfgang ;

Rader, Daniel J. ;

Melzer, David ;

Reich, David ;

Psaty, Bruce M. ;

Kleber, Marcus E. ;

Panagiotakos, Demosthenes B. ;

Willeit, Johann ;

Wennberg, Patrik ;

Woodward, Mark ;

Adamovic, Svetlana ;

Rimm, Eric B. ;

Meade, Tom W. ;

Gillum, Richard F. ;

Shaffer, Jonathan A. ;

Hofman, Albert ;

Onat, Altan ;

Sundstrom, Johan ;

Wassertheil-Smoller, Sylvia ;

Mellstrom, Dan ;

Gallacher, John ;

Cushman, Mary ;

Tracy, Russell P. .

LANCET, 2012, 379 (9822) :1205-1213

[58] Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma [J].

Smith, Richard A. ;

Bosonnet, Lorraine ;

Raraty, Michael ;

Sutton, Robert ;

Neoptolemos, John P. ;

Campbell, Fiona ;

Ghaneh, Paula .

AMERICAN JOURNAL OF SURGERY, 2009, 197 (04) :466-472

[59] An elevated neutrophil-lymphocyte ratio independently predicts mortality in chronic critical limb ischemia [J].

Spark, James Ian ;

Sarveswaran, Janahan ;

Blest, Nadia ;

Charalabidis, Peter ;

Asthana, Sonal .

JOURNAL OF VASCULAR SURGERY, 2010, 52 (03) :632-636

[60] Neutrophil-to-lymphocyte ratio associated with an increased risk of mortality in patients with critical limb ischemia [J].

Su, Min-I. ;

Liu, Cheng-Wei .

PLOS ONE, 2021, 16 (05)

← 1 2 3 4 5 6 7 8 →